A Boston-based company has passed an important hurdle in its effort to get FDA approval for its ovarian-cancer treatment.

Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. The new drug application for the treatment in ...

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and ...

Sharon Manson's 45-year career in oncology nursing includes roles from bedside nurse to assistant vice president of oncology ...